Therapeutic Asset Ratings
3,171 results matching 1 filter
91,583 assets · 7,906 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Tcr Transduced T-Cells
Ovarian Cancer
National Cancer Institute (NCI)
P2
CC
(46)
Anti-Cd7 Car-T Cells
T Lymphoblastic Leukemia/Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
P1
CC
(46)
azd6422 cldn18.2 car-t product
Digestive System Neoplasm
Peking University
P1
CC
(46)
Cb Car-Nk18.2
Pancreatic Adenocarcinoma
Zhejiang Provincial People's Hospital
P1
CC
(46)
cd19-ucart
T-Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P1
CC
(46)
dvx201
Acute Myeloid Leukemia
Coeptis Therapeutics
P1
CC
(46)
Lilrb4 Star-T
Acute Myeloid Leukemia
Hebei Yanda Ludaopei Hospital
P1
CC
(46)
RED BLOOD CELLS
Relapsing-Remitting Multiple Sclerosis
Cellerys AG
P1
CC
(46)
Tbio-4101
Ocular Melanoma
H. Lee Moffitt Cancer Center and Research Institute
P1
CC
(46)
Tbio-4101
Melanoma
H. Lee Moffitt Cancer Center and Research Institute
P1
CC
(46)
Ucar T-Cell
Autoimmune Disease
The Children's Hospital of Zhejiang University School of Medicine
P1
CC
(46)
Universal Donor Expanded Tgf-Beta-Imprinted Nk Cells
Plasma Cell Myeloma
Elvira Umyarova
P1
CC
(46)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines.
Esophageal Cancer
David Wald
P1/2
CC
(46)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines.
Gastric Cancer
David Wald
P1/2
CC
(46)
Allogenic Embryonic Stem Cell-Derived A9 Dopamine Progenitor Cell
Parkinson Disease
S.Biomedics Co., Ltd.
P1/2
CC
(46)
Anti-Cd30-Car-Transduced T Cells
Leukemia
Affiliated Hospital of Nantong University
P1/2
CC
(46)
Anti-Cd30-Car-Transduced T Cells
Lymphoma
Affiliated Hospital of Nantong University
P1/2
CC
(46)
cd19-ucart
Mantle Cell Lymphoma
University of Colorado, Denver
P1/2
CC
(46)
cd70-targeting car-t cells
Lymphoma
St. Jude Children's Research Hospital
P1/2
CC
(46)
Cea Car-T Cells
Gastric Cancer
Chongqing Precision Biotech Co., Ltd
P1/2
CC
(46)
Cea Car-T Cells
Lung Cancer
Chongqing Precision Biotech Co., Ltd
P1/2
CC
(46)
Cea-Targeted Car-T
Colon Carcinoma
Chongqing Precision Biotech Co., Ltd
P1/2
CC
(46)
Cea-Targeted Car-T
Esophageal Cancer
Chongqing Precision Biotech Co., Ltd
P1/2
CC
(46)
Cea-Targeted Car-T
Gastric Cancer
Chongqing Precision Biotech Co., Ltd
P1/2
CC
(46)
Cea-Targeted Car-T
Lung Cancer
Chongqing Precision Biotech Co., Ltd
P1/2
CC
(46)
Showing 826 to 850 of 3,171 assets
Previous
Page 34 of 127
Next
